IMMULITE® 2000/2000 XPi Allergy Testing

Allergy prevalence and severity is increasing globally

Reported allergies are more prevalent than ever before and are sending more and more people to hospitals on a global scale.

Allergens

The prevalence of allergic diseases has continued to increase in the industrialized world for more than 50 years.1

Worldwide

Worldwide, sensitization rates to one or more common allergens among school children are approaching 40–50%.1

Hospital

Hospitalization for allergy related anaphylaxis hospitalization on the rise in the US, Australia, Europe and other regions.2

It can also offer component testing in some food allergies, meaning the test can determine the exact proteins that could trigger a response and can even predict the severity of a potential reaction.

  • Standardized for more quantifiable results and informed decision making.
  • Fewer false positives for patients with sensitive skin, hives, and eczema.
  • Doesn't require discontinuation of medication or patient adherence to pretest instruction.
  • Enables component testing in food allergies by degerming the exact triggering proteins.


Blood tests can predict the severity of the allergy, as opposed to just its presence. 

IMMULITE® 2000/2000 XPi 3gAllergy: Proven Performance

Care delivery

Enhance patient care with reliable assay performance from a simple blood test that uses quality extracts that are thoroughly evaluated for potency and allergenic composition. Third generation chemiluminescent technology and proprietary liquid allergens for enhanced sensitivity and specificity can increase confidence in results.

Patient experience

Collect quantifiable results for more informed care decisions—derived from a less invasive test that doesn’t require medication cessation or carry the risk of potential reactions. 

Operational efficiency

Improve operational efficiency by centralizing allergy testing onto an easy-to-use platform that offers full automation connectivity, simple assay adjustments, bar-coded specific allergens, and an AutoStart* feature.

1
2